Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial.
Paul B RomesserEric J ShermanKarissa A WhitingMargaret L HoAshok R ShahaMona M SabraNadeem RiazTodd E WaldenbergChristopher R SabolIan GanlySean M McBrideJames A FaginZhigang ZhangR Michael TuttleRichard J WongNancy Y LeePublished in: Cancer (2021)
In light of the excellent locoregional control rates achieved with CC-IMRT and its acceptable toxicity profile as confirmed by functional assessments and patient-reported outcomes, CC-IMRT may be preferred over IMRT alone.